Different Effects of Serotonin (5-HT) Uptake Blockers in Caudate Nucleus and Hippocampus of the Rabbit: Role of Monoamine Oxidase in Dopaminergic Terminals
Overview
Authors
Affiliations
Slices of rabbit hippocampus or caudate nucleus were incubated with [3H]-5-HT (0.1 microM, 60 min) or with [3H]-DA. In hippocampal tissue, the 5-HT uptake blockers chlorimipramine, fluvoxamine, and 6-nitroquipazine (0.1, 1, 10 microM) reduced the percentage content of [3H]-5-HT in a concentration dependent manner. The degree of inhibition of [3H]-5-HT content produced by the 5-HT uptake inhibitors was not affected by the MAO inhibitors pargyline or amezinium (which by themselves enhanced [3H] loading) or the catecholamine uptake inhibitor nomifensine (which by itself did not affect [3H] loading). In caudate nucleus tissue, however, the [3H]-5-HT accumulation was reduced only at the highest concentration of the 5-HT uptake blockers (10 microM). In the additional presence of the MAO inhibitors or nomifensine (which by themselves increased or diminished, respectively, the [3H] labelling) the 5-HT uptake inhibitors became more potent in reducing the percentage [3H]-5-HT accumulation of caudate nucleus slices. These results indicate (1) that a false labelling of [3H]-5-HT into dopaminergic terminals in the caudate nucleus can be prevented by nomifensine, (2) that the 5-HT uptake blockers seem to accumulate within the dopaminergic terminals, where they may display a MAO inhibitory property. The 5-HT uptake blockers were ineffective on the percentage tritium accumulation of caudate nucleus slices incubated with [3H]-DA, regardless of the presence of pargyline or nomifensine. Tritiated DA and deaminated [3H]-metabolites were separated in the superfusate of [3H]-DA-release experiments in caudate nucleus tissue.(ABSTRACT TRUNCATED AT 250 WORDS)
Presynaptic control of serotonin on striatal dopamine function.
Navailles S, De Deurwaerdere P Psychopharmacology (Berl). 2010; 213(2-3):213-42.
PMID: 20953589 DOI: 10.1007/s00213-010-2029-y.
Mantovani M, Dooley D, Weyerbrock A, Jackisch R, Feuerstein T Br J Pharmacol. 2009; 158(7):1848-56.
PMID: 19912224 PMC: 2801225. DOI: 10.1111/j.1476-5381.2009.00478.x.
Berger B, Rothmaier A, Wedekind F, Zentner J, Feuerstein T, Jackisch R Br J Pharmacol. 2006; 148(6):795-806.
PMID: 16751796 PMC: 1617080. DOI: 10.1038/sj.bjp.0706782.
Steffens M, Engler C, Zentner J, Feuerstein T Br J Pharmacol. 2004; 141(7):1193-203.
PMID: 14993102 PMC: 1574880. DOI: 10.1038/sj.bjp.0705706.
Lupp A, Lucking C, HEDLER L, Feuerstein T Naunyn Schmiedebergs Arch Pharmacol. 1993; 347(2):141-6.
PMID: 8474535 DOI: 10.1007/BF00169259.